Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Dobrindt trifft Knaus, den grünen Ideologen der Balkanroute (Tichys Einblick) +++ KNAUS TABBERT Aktie -3,69%

LAKEFRONT BIOTHERAPEUTICS Aktie

 >GALAPAGOS NV Aktienkurs 
31.24 EUR    +2.0%    (TradegateBSX)
Ask: 31.26 EUR / 160 Stück
Bid: 31.22 EUR / 160 Stück
Tagesumsatz: 385 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
GALAPAGOS NV Aktie über LYNX handeln
>GALAPAGOS NV Performance
1 Woche: +2,8%
1 Monat: +15,2%
3 Monate: +24,8%
6 Monate: +27,1%
1 Jahr: +14,1%
laufendes Jahr: +8,8%
>LAKEFRONT BIOTHERAPEUTICS Aktie
Name:  LAKEFRONT BIOTHERAPEUTICS (GALAPAGOS)
Land:  Belgien
Sektor:  Gesundheit
ISIN/ Wkn:  BE0003818359 / A0EAT9
Symbol/ Ticker:  GXE (Frankfurt)
Kürzel:  FRA:GXE, ETR:GXE, GXE:GR
Index:  AEX
Profil:  Lakefront Biotherapeutics is a clinical-stage biotechnology company focused on the discovery and development of small molecule therapies targeting unmet medical needs. Headquartered in Belgium, it operates in the healthcare sector, leveraging advance..
>Volltext..
Marktkapitalisierung:  1994.53 Mio. EUR
Unternehmenswert:  -191.82 Mio. EUR
Umsatz:  952.75 Mio. EUR
EBITDA:  -
Nettogewinn:  818.2 Mio. EUR
Gewinn je Aktie:  12.42 EUR
Schulden:  3.19 Mio. EUR
Liquide Mittel:  97.29 Mio. EUR
Operativer Cashflow:  -143.69 Mio. EUR
Bargeldquote:  45.17
Umsatzwachstum:  223.08%
Gewinnwachstum:  -
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  LAKEFRONT BIOTHERAPEUTICS, LAKEFRONT BIO, LAKEFRONT BIOTHERAPEUTIC, GALAPAGOS NV
Letzte Datenerhebung:  16.11.26
>GALAPAGOS NV Kennzahlen
Aktien/ Unternehmen:
Aktien: 65.66 Mio. St.
Frei handelbar: 67.6%
Leerverk. Aktien: -
Rückkaufquote: 2.1%
Mitarbeiter: 452
Umsatz/Mitarb.: 2.62 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 0.24%
Bewertung:
KGV: 2.53
KGV lG: -
KUV: 2.1
KBV: 0.62
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 98.05%
Gewinnmarge: 85.23%
Operative Marge: 64.5%
Managementeffizenz:
Gesamtkaprendite: 23.21%
Eigenkaprendite: 27.82%
>GALAPAGOS NV Peer Group
Gesundheit, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Onkologie/ Krebs- Behandlung
 
16.11.26 - 08:42
Lakefront Biotherapeutics initiates new €50M share repurchase program (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
16.11.26 - 07:30
Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program (GlobeNewswire EN)
 
Mechelen, Belgium; November 16, 2026; 7.30 AM CET regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the initiation of a new share repurchase program of up to €50 million, following completion of its initial €50 million program announced on June 9, 2026....
11.11.26 - 22:09
Lakefront Biotherapeutics GAAP EPS of €0.20, revenue of €26.1M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
11.11.26 - 22:02
Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update (GlobeNewswire EN)
 
Gamgertamig poster accepted for presentation at the 2026 ASH1 Annual Meeting, featuring data from ongoing Phase 1b studies that suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an “immune reset”...
10.11.26 - 22:03
Lakefront to Present at the 2026 Jefferies Global Healthcare Conference in London (GlobeNewswire EN)
 
Mechelen, Belgium; November 10, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the 2026 Jefferies Global Healthcare Conference in London at 2:00 pm GMT (9:00 am ET) on Tuesday, November 17, 2026....
04.11.26 - 15:03
Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting (GlobeNewswire EN)
 
Gamgertamig data from ongoing Phase 1b studies suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an “immune reset”...
02.11.26 - 22:03
Lakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of Directors (GlobeNewswire EN)
 
Dr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board...
21.10.26 - 19:45
Lakefront Biotherapeutics - Sponsored ADR (LKFT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
 
Lakefront Biotherapeutics - Sponsored ADR (LKFT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....
10.08.26 - 22:06
Lakefront Biotherapeutics reports Q2 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.07.26 - 22:03
Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi (GlobeNewswire EN)
 
Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research & Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors....
29.06.26 - 22:03
Lakefront Receives Transparency Notification from Madison Avenue Partners (GlobeNewswire EN)
 
Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners....
09.06.26 - 22:15
Lakefront Biotherapeutics launches €50M share buyback program (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.06.26 - 22:03
Lakefront Announces Initiation of €50 Million Stock Repurchase Program (GlobeNewswire EN)
 
Mechelen, Belgium; June 9, 2026, 22:01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the “Program”), under which the Company may repurchase ordinary shares for an aggregate amount of up to €50 Million. Repurchases under the Program may be made no later than December 31, 2026. The Program is entered into with Morgan Stanley & Co International PLC.  ...
08.06.26 - 22:03
Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer (GlobeNewswire EN)
 
Mechelen, Belgium; June 8, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership role supports the Company's strategic transformation following its acquisition of Ouro Medicines operational assets announced on June 4, 2026.1 Eric will report to Henry Gosebruch, CEO and join the Company's Management Committee....
15.05.26 - 11:30
Galapagos meldet Umsatzeinbruch um 91 % und kündigt strategische Neuausrichtung an (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
07.05.26 - 15:06
Galapagos Q1 2026: Gewinn pro Aktie übertrifft Erwartungen, Umsatz verfehlt Ziel deutlich (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
06.05.26 - 23:27
Galapagos GAAP EPS of $0.20 beats by $1.72, revenue of $6.5M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.05.26 - 22:03
Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire EN)
 
Galapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM (Euronext & NASDAQ: LKFT)Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to close in the Second Quarter of 2026Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash remaining for additional strategic transactions and other capital allocation prioritiesYear-end 2026 cash and financial investments balance expected to be approximately €2BManagement to host conference call on May 7, 2026, at 14:00 CET / 8:00 am ETMechelen, Belgium; May 6, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the first quarter of 2026 and provided a business update.“Having joined the company just one year ago, I'm thrilled with our progress. I am looking forward to consummating our partnership with Gilead and addin...
28.04.26 - 22:03
Galapagos′ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders′ Meetings 2026 (GlobeNewswire EN)
 
Mechelen, Belgium; April 28, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the Company's Annual and Extraordinary Shareholders' Meetings (AGM and EGM) held on 28 April 2026 were approved....
31.03.26 - 08:48
Galapagos Enters Framework Agreement With Gilead In Connection With Ouro Deal (AFX)
 
FOSTER CITY (dpa-AFX) - Galapagos (GLPG, GLPG.AS) has entered into a binding agreement with Gilead Sciences (GILD) in connection with Gilead's agreement to acquire all of the outstanding equity in......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Geschmack hängt nicht an unseren Bedürfnissen. Der Mann muß schon sehr gesittet sein, wenn er eine Frau nach Geschmack wählen soll. - Immanuel Kant
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!